¼¼°èÀÇ µ¿¹°¿ë »ê¼Ò ¿ä¹ý ½ÃÀåÀº 2024³â 12¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í CAGR 8.5%¸¦ ³ªÅ¸³» 2034³â¿¡´Â 27¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ½À´Ï´Ù. ¹Ý·Áµ¿¹°ÀÇ °Ç°¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, ¹Ý·Áµ¿¹°ÀÇ Àΰ£È, °í±Þ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÁÖÀÎÀÇ ÁöÃâ ÀÇ¿å Áõ°¡°¡ µ¿¹° ÀÇ·á ÇöÀå¿¡¼ÀÇ »ê¼Ò ¿ä¹ýÀÇ Ã¤¿ëÀ» °ÈÇϰí ÀÖ½À´Ï´Ù. ¼º Æó»ö¼º ÆóÁúȯ(COPD) ¹× ±âŸ È£Èí±â ÇÕº´Áõ°ú °°Àº Áõ»óÀº ƯÈ÷ ¿À¿° ¼öÁØÀÌ ³ôÀº µµ½Ã ȯ°æ¿¡¼ Á¡Á¡ ´õ ÈçÇØÁö°í ÀÖ½À´Ï´Ù. µ¿¹°¿ë »ê¼Ò ¿ä¹ýÀº ¼ö¼ú ÈÄ È¸º¹°ú ½É°¢ÇÑ Äɾ À§ÇÑ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ¸·Î ´ëµÎÇØ ¿Ô½À´Ï´Ù. µ¡ºÙ¿© ºñ¸¸°ú °ü·ÃµÈ ÇÕº´Áõ Áõ°¡³ª ¹Ý·Áµ¿¹°ÀÇ °í·ÉÈ¿¡ ÀÇÇØ Áø·á¼Ò³ª °¡Á¤¿¡¼ÀÇ Áö¼ÓÀû¡¤±ä±ÞÀûÀÎ »ê¼Ò ¿ä¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
ÇöÀç µ¿¹°º´¿øÀ̳ª Àü¹®Å¬¸®´Ð Áß¿¡´Â »ýÁ¸À² Çâ»ó°ú Ä¡·á¼ºÀû °³¼±À» ¸ñÀûÀ¸·Î ³óÃà±â, ºñ° Ä«Å×ÅÍ, °íÈ¿À² »ê¼Ò¸¶½ºÅ© µîÀÇ °íµµÀÇ »ê¼Ò¿ä¹ý±â±â¸¦ µµÀÔÇÏ´Â °÷ÀÌ ´Ã¾î³ª°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ »ê¼Ò ³óÃà±â´Â ¿¬¼ÓÀûÀÎ »ê¼Ò À¯·®À» Á¦°øÇϱ⠶§¹®¿¡ ƯÈ÷ ¸¸¼ºÀûÀÎ Áõ»ó¿¡ ´ëÇØ¼´Â Áø·á¼Ò³»¿Í Áý¿¡¼ÀÇ ÄɾîÀÇ ¾çÂÊ ¸ðµÎ¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ±âÁ¸ÀÇ »ê¼Ò º½º£¿¡ ºñÇØ, ÈÞ´ëÇü »ê¼Ò ³óÃà±â´Â Áö¼Ó°¡´É¼ºÀÌ ³ô°í, À¯Áö°ü¸®µµ Àû°Ô À¯ÁöÇϱ⠶§¹®¿¡ °³¾÷
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 12¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 27¾ï ´Þ·¯ |
CAGR | 8.5% |
½ÃÀåÀº Á¦Ç° À¯Çüº°·Î µ¿¹°¿ë »ê¼Ò³óÃà±â¿Í ¾×¼¼¼¸®·Î ±¸ºÐµË´Ï´Ù. °í·ÉÀÇ ¹Ý·Áµ¿¹°Àº Æó·Å, ±â°üÁö¿°, È£Èí °ï¶õ ÁõÈıº µîÀÇ Áúº´¿¡ °É¸®´Â °æ¿ì°¡ ¸¹¾Æ, ±× Ä¡·á¿¡´Â »ê¼Ò ¿ä¹ýÀÌ ¹Ù¶÷Á÷ÇÕ´Ï´Ù.
µ¿¹°À¯Çüº°·Î º¸¸é, ½ÃÀåÀº ¼Òµ¿¹°°ú ´ëµ¿¹°·Î ºÐ·ùµÇ¸ç, 2024³â Á¡À¯À²Àº ÀÛÀº µ¿¹°ÀÌ 60%¸¦ Â÷ÁöÇß½À´Ï´Ù. ºÏ¹Ì¿¡¼´Â °·ÂÇÑ ¹Ý·Áµ¿¹° °Ç° °ü¸® ÀÎÇÁ¶ó, ³ôÀº ¹Ý·Áµ¿¹° »çÀ°·ü, ¸¸¼º È£Èí±â Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó µ¿¹°¿ë »ê¼Ò ¿ä¹ý ½ÃÀåÀº 2024³â ¼¼°è Á¡À¯À²ÀÇ 39.9%¸¦ Â÷ÁöÇß½À´Ï´Ù.
Imex Medical Limited, AEOLUS International Pet Products, Drive DeVilbiss International, Koninklijke Philips, Vetland Medical, RWD Life Science, Airnetic, Shinova Systems, BMW Animal Technology, Longfian ScitechµîÀÇ ÁÖ¿ä ±â¾÷ÀÌ ½ÃÀå Àü¸ÁÀ» Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷Àº ±â¼ú Çõ½ÅÀ» ¿ì¼±ÇØ, º¸´Ù ÈÞ´ë¿ëÀ¸·Î ºñ¿ë È¿°ú°¡ ³ô°í, È¿À²ÀûÀÎ »ê¼Ò ¿ä¹ý ½Ã½ºÅÛÀ» µµÀÔÇϱâ À§Çؼ ¿¬±¸ °³¹ß¿¡ ´Ù¾×ÀÇ ÅõÀÚ¸¦ ½Ç½ÃÇß½À´Ï´Ù.
The Global Veterinary Oxygen Therapy Market was valued at USD 1.2 billion in 2024 and is estimated to grow at a CAGR of 8.5% to reach USD 2.7 billion by 2034. This growth trend reflects a significant transformation in veterinary healthcare as oxygen therapy becomes a core component in treating pets with respiratory disorders and chronic illnesses. Rising awareness about pet health, the humanization of pets, and increased willingness among pet owners to spend on advanced treatment solutions are reinforcing the adoption of oxygen therapy across veterinary settings. Conditions like pneumonia, asthma, chronic obstructive pulmonary disease (COPD), and other respiratory complications are becoming increasingly common, especially in urban environments where pollution levels are high. Veterinary care is undergoing a shift toward more patient-friendly, non-invasive solutions, with oxygen therapy emerging as a reliable method for post-surgical recovery and critical care. In addition to that, the rising prevalence of obesity-related complications and aging pet populations are accelerating the demand for continuous and emergency oxygen support in clinics and at home.
A growing number of veterinary hospitals and specialty clinics are now incorporating advanced oxygen therapy devices such as concentrators, nasal catheters, and high-efficiency oxygen masks to improve survival rates and enhance treatment outcomes. Post-operative complications often require oxygen therapy for stabilized recovery, making it a critical part of intensive veterinary care. Technological innovations, especially the introduction of portable oxygen concentrators, have significantly improved care delivery. These devices offer continuous oxygen flow, making them ideal for both in-clinic and at-home care, particularly for chronic conditions. Compared to traditional oxygen cylinders, portable concentrators are more sustainable and require less maintenance, offering cost-effective solutions for both practitioners and pet owners.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $1.2 Billion |
Forecast Value | $2.7 Billion |
CAGR | 8.5% |
The market is segmented by product type into veterinary oxygen concentrators and accessories. The oxygen concentrator segment alone generated USD 984.5 million in 2024. This includes both stationary and portable devices, which are being increasingly used due to a rise in surgical interventions and emergency respiratory cases. Aging pets often suffer from ailments such as pneumonia, bronchitis, and respiratory distress syndrome, for which oxygen therapy is the preferred method of care. The convenience, efficiency, and eco-friendliness of concentrators have made them a preferred choice among veterinary professionals.
By animal type, the market is categorized into small and large animals, with the small animal segment accounting for a 60% share in 2024. This dominance is linked to the widespread ownership of small pets like pugs, bulldogs, and Persian cats, which are prone to breathing disorders. In North America, the veterinary oxygen therapy market accounted for 39.9% of the global share in 2024, thanks to strong pet healthcare infrastructure, higher pet ownership rates, and growing awareness of chronic respiratory conditions.
Leading companies such as Imex Medical Limited, AEOLUS International Pet Products, Drive DeVilbiss International, Koninklijke Philips, Vetland Medical, RWD Life Science, Airnetic, Shinova Systems, BMV Animal Technology, and Longfian Scitech are shaping the market landscape. These players are prioritizing innovation and investing heavily in research and development to introduce more portable, cost-effective, and efficient oxygen therapy systems. They are also forming strategic alliances with veterinary hospitals and clinics to enhance their service networks and launching cutting-edge devices to address the evolving needs of veterinary care.